NL-OMON37966尚未招募不适用
: Long-term follow up of growth and bone mineralization of former preterm infants - FoBoMin
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 110 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 11（—）
入选标准
- •Informed consent
- •A participant of our previous study (birth at gestational age below 34 weeks, admission to the NICU of the Radboud UMC on the first day of life, expected duration of parenteral nutrition more than 5 days)
排除标准
- •Not full filling inclusion criteria
- •At our previous study asphyxia, congenital malformation, renal and hepatic insufficiency at birth were exclusion criteria.
研究者
相似试验
招募中
不适用
ong-term follow up of growth and bone mineralization of former preterm infantsFoBoMinpreterm infantsbone mineralizationlengthNL-OMON28045Radboud University Medical Centre110
已完成
不适用
ong-term observation on adult bone mineral density and lifestyle-related diseases prevention with daily lemon intake in Osakikamijima Town, Hiroshima prefectureJPRN-UMIN000025818SAPPORO HOLDINGS Ltd.170
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-BGObsEva S.A.400
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-PLObsEva S.A.400
进行中（未招募）
1 期
ong-term bone mineral density follow-up in subjects completing PRIMROSE 1 or PRIMROSE 2Treatment of heavy menstrual bleeding associated with uterine fibroids.MedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864EUCTR2021-000452-19-HUObsEva S.A.400